Antares Pharma (ATRS) Q4 results:
Revenues: $37.8M (+101.1%); Product sales: $28.5M
(+100.7%); Licensing and development revenue: $3.2M (+190.9%);
Royalties: $6.2M (+77.1%).
Xyosted: $8.4M; Otrexup: $5.6M.
Net Income: $4.7M (-23.0%); EPS: $0.03 (-25.0%); Quick Assets: $45.7M (+63.8%).
2020 guidance: Revenue: $135M – 155M.
Shares are up 5% premarket.
https://seekingalpha.com/news/3547926-antares-pharmaplus-5-premarket-on-q4-beat
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.